BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 11708768)

  • 1. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection.
    Hernández Marin M; Márquez Bocalandro Y; Vallejo RV; Rodríguez Tanty C; Higginson Clark D; Pozo Peña L; Silva León C
    Prep Biochem Biotechnol; 2003 Feb; 33(1):29-38. PubMed ID: 12693813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
    Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
    Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic mixture of synthetic peptides for the immunodiagnosis of HTLV I/II infection.
    Bocalandro YM; Marin MH; Vallejo RA; Peña LP; León CS; Martínez GR; Tanty CR; Clarke DH; Velázquez SB
    J Immunoassay Immunochem; 2004; 25(3):205-14. PubMed ID: 15461383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric synthetic peptides from the nucleocapsid p24 protein of human immunodeficiency virus type-1.
    Hernández M; Rodríguez I; Pozo L; Rivero J
    Biochem Biophys Res Commun; 2001 Mar; 282(1):1-3. PubMed ID: 11263961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
    Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
    Tanaka Y; Tanaka R; Hoshino H
    Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus.
    Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS
    Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection.
    Hernández M; Pozo L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 May; 272(1):259-62. PubMed ID: 10872836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunoreactivity of synthetic peptides, corresponding to B-cellular epitopes of human type I T-lymphotrophic virus structural proteins].
    Rasuli AM; Klepikov NN; Andreev SM; Sidorova MV; Vafina MG; Seniuta NB; Pavlish OA; Syrtsev AV; Gurtsevich VE
    Mol Biol (Mosk); 1993; 27(4):880-7. PubMed ID: 8361494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immunodominant epitopes in envelope glycoprotein of human T lymphotropic virus type II.
    Lal RB; Rudolph DL; Kaplan JE; Hjelle B; Levine PH; Coligan JE; Viscidi RP
    Virology; 1992 Jan; 186(1):274-9. PubMed ID: 1727602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.